Analysts’ Recent Ratings Changes for Intellia Therapeutics (NTLA)

Intellia Therapeutics (NASDAQ: NTLA) has recently received a number of price target changes and ratings updates:

• 3/7/2026 – Intellia Therapeutics was upgraded by Wall Street Zen from “sell” to “hold”.
• 3/4/2026 – Intellia Therapeutics was upgraded by JonesTrading from “hold” to “buy”. They now have a $29.00 price target on the stock.
• 3/3/2026 –
• 3/3/2026 – Intellia Therapeutics had its price target lowered by Canaccord Genuity Group Inc. from $54.00 to $48.00. They now have a “buy” rating on the stock.
• 3/3/2026 – Intellia Therapeutics had its price target raised by Leerink Partners from $27.00 to $29.00. They now have an “outperform” rating on the stock.
• 3/3/2026 – Intellia Therapeutics had its price target raised by Royal Bank Of Canada from $9.00 to $15.00. They now have a “sector perform” rating on the stock.
• 3/3/2026 – Intellia Therapeutics had its price target raised by Wells Fargo & Company from $12.00 to $15.00. They now have an “equal weight” rating on the stock.
• 3/3/2026 – Intellia Therapeutics had its price target raised by HC Wainwright from $25.00 to $30.00. They now have a “buy” rating on the stock.
• 3/3/2026 – Intellia Therapeutics had its price target raised by Citizens Jmp from $21.00 to $28.00. They now have a “market outperform” rating on the stock.
• 3/2/2026 – Intellia Therapeutics had its “neutral” rating reaffirmed by Bank of America Corporation.
• 3/2/2026 – Intellia Therapeutics was upgraded by William Blair from “market perform” to “outperform”.
• 2/27/2026 – Intellia Therapeutics had its “buy” rating reaffirmed by Chardan Capital. They now have a $26.00 price target on the stock.
• 1/28/2026 – Intellia Therapeutics was given a new $25.00 price target by KeyCorp.
• 1/28/2026 – Intellia Therapeutics had its price target raised by HC Wainwright from $15.00 to $25.00. They now have a “buy” rating on the stock.
• 1/27/2026 – Intellia Therapeutics was given a new $7.00 price target by Robert W. Baird.
• 1/22/2026 – Intellia Therapeutics had its “sell (d-)” rating reaffirmed by Weiss Ratings.

Insider Transactions at Intellia Therapeutics

In other Intellia Therapeutics news, EVP Birgit C. Schultes sold 8,508 shares of Intellia Therapeutics stock in a transaction that occurred on Monday, January 5th. The stock was sold at an average price of $9.21, for a total transaction of $78,358.68. Following the transaction, the executive vice president owned 98,533 shares of the company’s stock, valued at $907,488.93. The trade was a 7.95% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CEO John M. Leonard sold 34,146 shares of the business’s stock in a transaction that occurred on Monday, January 5th. The shares were sold at an average price of $9.21, for a total value of $314,484.66. Following the completion of the sale, the chief executive officer owned 1,013,339 shares of the company’s stock, valued at approximately $9,332,852.19. This represents a 3.26% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 53,051 shares of company stock worth $488,600. Corporate insiders own 3.10% of the company’s stock.

Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.